Elon Musk Signs Australian Pact... Sends One Company Soaring Overnight
Tesla is facing a critical lithium shortage. Could this company be the next Tesla savior?
Click Here To Get The Full Story

GTBP Insider Trading (GT Biopharma)

Insider Ownership Percentage: 9.16%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $174,927.00

GT Biopharma Insider Trading History Chart

This chart shows the insider buying and selling history at GT Biopharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

GT Biopharma Share Price & Price History

Current Price: $15.26
Price Change: Price Decrease of -0.18 (-1.17%)
As of 06/23/2021 01:00 AM ET

This chart shows the closing price history over time for GTBP up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Data Firm Predicts That Retail Cannabis Will Hit $41 Billion By 2025
It's clear that there's a giant "Green Boom Coming." And here's how you can get it on it...
Get The Full Report Here

GT Biopharma Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/18/2020Steven W WeldonDirectorSell200,000$0.30$60,000.00
12/15/2020Steven W WeldonDirectorSell396,300$0.29$114,927.00
See Full Table
Insider Trading at GT Biopharma?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for GT Biopharma and related companies.

SEC Filings (Institutional Ownership Changes) for GT Biopharma (OTCMKTS:GTBP)

2.56% of GT Biopharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at GTBP by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

GT Biopharma Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/19/2021Virtu Financial LLC22,741$0.16M0.0%N/A0.080%Search for SEC Filing on Google Icon
5/19/2021Squarepoint Ops LLC16,543$0.11M0.0%N/A0.058%Search for SEC Filing on Google Icon
5/18/2021Millennium Management LLC27,895$0.19M0.0%N/A0.098%Search for SEC Filing on Google Icon
5/17/2021Royal Bank of Canada24,542$0.17M0.0%N/A0.086%Search for SEC Filing on Google Icon
5/12/2021Northern Trust Corp34,387$0.24M0.0%N/A0.121%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC130,388$0.89M0.0%N/A0.459%Search for SEC Filing on Google Icon
5/12/2021UBS Group AG3,918$27K0.0%N/A0.014%Search for SEC Filing on Google Icon
5/11/2021Davy Global Fund Management Ltd26,321$0.18M0.0%N/A0.093%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
GT Biopharma logo
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. The company develops various immuno-oncology product candidates, including GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and other CD33+ hematopoietic malignancies; GTB-C3550, a follow-on to its lead candidates TriKE, GTB-3550; GTB-4550, a single-chain tri-specific single chain variable fragments (scFv) recombinant fusion protein conjugate for the treatment of PD-L1+ solid tumor cancers; and GTB-5550, a single-chain tri-specific scFv recombinant fusion protein conjugate for the treatment of B7H3+ solid tumor cancers. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology; and a collaboration agreement with Cytovance Biologics to provide development services for a TriKE therapeutic for the treatment of coronavirus infection. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Beverly Hills, California.
Read More on GT Biopharma

Today's Range

Now: $15.26
Low: $15.04
High: $16.59

50 Day Range

MA: $14.60
Low: $9.13
High: $18.96

52 Week Range

Now: $15.26
Low: $2.04
High: $19.73

Volume

299,422 shs

Average Volume

478,103 shs

Market Capitalization

$322.41 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.28

Who are the company insiders with the largest holdings of GT Biopharma?

GT Biopharma's top insider investors include:
  1. Steven W Weldon (Director)

Who are the major institutional investors of GT Biopharma?

GT Biopharma's top institutional investors include:
  1. Geode Capital Management LLC — 0.46%
  2. Northern Trust Corp — 0.12%
  3. Millennium Management LLC — 0.10%
  4. Davy Global Fund Management Ltd — 0.09%
  5. Royal Bank of Canada — 0.09%
  6. Virtu Financial LLC — 0.08%

Which major investors are buying GT Biopharma stock?

During the previous quarter, GTBP stock was bought by institutional investors including:
  1. Geode Capital Management LLC
  2. Northern Trust Corp
  3. Millennium Management LLC
  4. Davy Global Fund Management Ltd
  5. Royal Bank of Canada
  6. Virtu Financial LLC
  7. Squarepoint Ops LLC
  8. UBS Group AG
Data Firm Predicts That Retail Cannabis Will Hit $41 Billion By 2025
It's clear that there's a giant "Green Boom Coming." And here's how you can get it on it...
Get The Full Report Here